
    
      A multicenter randomized phase â…¢ clinical trial of gemcitabine in combination with
      capecitabine versus gemcitabine plus carboplatin as first-line treatment in triple-negative
      recurrent or metastatic breast cancer.The primary endpoints of the study is progression free
      survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival
      (OS) and safety.
    
  